# colorectal cancer - grok-4.6

- Benchmark system: E2seq + Agent RAG
- Repeat: 3
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: xAI / grok-4.6
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 44847
- Completion tokens: 23475
- Reasoning tokens: 17998
- Total tokens: 68322
- API requests reported: 3
- Elapsed seconds: 103.758
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 2/5; original repeat 3; model vendor: xAI

---
**1. Overall biological interpretation**  
The prognostic transcriptomic results in colorectal tumor tissue for overall survival identify 54 risk-associated genes (HR > 1) and 46 protective-associated genes (HR < 1), with the strongest signals (FDR ≤ 0.01) concentrated in mitochondrial energy metabolism (predominantly protective) and epithelial-mesenchymal transition/motility programs (predominantly risk). These genes collectively point to a biological theme in which tumors maintaining mitochondrial respiratory function and metabolic flexibility tend to associate with better survival, whereas those exhibiting EMT-driven plasticity and regulatory signaling confer worse outcomes. This pattern is consistent with known CRC biology in which metabolic rewiring and invasive phenotypes influence disease progression and therapy response.

**2. Core biological programs**  

**Program name:** Mitochondrial oxidative phosphorylation and ATP production  
**Direction or prognostic association:** Protective (HR < 1)  
**Major supporting genes:** NDUFA9, ATP23, ATP5G1, ATP5B, CS  
**The most appropriate standardized pathway:** Oxidative phosphorylation (KEGG)  
**Explanation of why the supporting genes collectively indicate this biological program:** These genes encode subunits of the electron transport chain, ATP synthase, and metabolic enzymes that generate ATP and maintain bioenergetic homeostasis; their consistent protective association indicates that preserved mitochondrial function correlates with improved OS, likely by supporting tumor cell energy demands or limiting metabolic stress in the tumor microenvironment.  
**The strength of the evidence and the major limitations of the interpretation:** Direct evidence from the input dataset (multiple genes with HR < 1 and FDR values ranging 0.0066–0.0519); pathway/KEGG annotation support; disease/tissue-specific evidence from CRC literature for metabolic reprogramming. Limitations include potential confounding by general tumor hypoxia or necrosis rather than CRC-specific mechanisms; no independent-cohort HR statistics provided.

**Program name:** Epithelial-mesenchymal transition (EMT) and cell motility  
**Direction or prognostic association:** Risk-associated (HR > 1)  
**Major supporting genes:** ZEB1-AS1, DCBLD2, TPM4, NIN, ITGBL1  
**The most appropriate standardized pathway:** Hallmark EMT or KEGG Focal adhesion  
**Explanation of why the supporting genes collectively indicate this biological program:** These genes promote mesenchymal transition, cytoskeletal remodeling, and migratory signaling; their risk association indicates that EMT activation facilitates invasion and metastasis, driving poorer OS in CRC.  
**The strength of the evidence and the major limitations of the interpretation:** Direct evidence from the input dataset (five genes with HR 1.28–1.41 and FDR ≤ 0.0306); published literature for several (e.g., ZEB1-AS1 and TPM4 in EMT networks); limitations include indirect gene-function mapping without direct physical-interaction data; gene names are largely non-coding or poorly annotated, reducing mechanistic specificity.

**Program name:** Glyoxylate and dicarboxylate metabolism  
**Direction or prognostic association:** Protective (HR < 1 for key genes)  
**Major supporting genes:** CS, ASL, OGDHL, GLYCTK  
**The most appropriate standardized pathway:** Glyoxylate and dicarboxylate metabolism (KEGG)  
**Explanation of why the supporting genes collectively indicate this biological program:** These enzymes facilitate metabolic flexibility by converting glyoxylate to succinate, bypassing toxic intermediates and supporting anaplerotic pathways; their protective association suggests that efficient glyoxylate metabolism may enhance tumor adaptability or reduce oxidative stress, influencing OS.  
**The strength of the evidence and the major limitations of the interpretation:** Direct evidence from the input dataset (four genes with HR 0.69–0.75 and FDR ≤ 0.0744); KEGG pathway annotation; limitations include reliance on only a subset of genes; no formal enrichment statistic provided, so the program is hypothesis-generating rather than statistically enriched.

**3. Key genes and interaction modules**  
**INHBB (risk, HR = 1.433, FDR = 0.001093):** Potential role in TGF-β signaling and tumor progression; literature links high expression to poor CRC prognosis and malignant phenotypes. Relationship: indirect regulatory interaction with EMT-related genes via SMAD pathways.  
**ZEB1-AS1 (risk, HR = 1.372, FDR = 0.008647):** Core EMT regulator; role in mesenchymal transition and invasion within the EMT program. Relationship: regulatory interaction with DCBLD2 and TPM4 (co-expression or pathway co-membership).  
**NDUFA9 (protective, HR = 0.6886, FDR = 0.008647):** Mitochondrial complex I subunit; role in the oxidative phosphorylation program. Relationship: pathway co-membership with ATP5 genes.  
**CDX2 (protective, HR = 0.7478, FDR = 0.035501):** Intestinal differentiation factor; role in suppressing Wnt/β-catenin signaling and tumor proliferation. Relationship: indirect relationship via differentiation networks; supported by published CRC literature.  
**NT5E (risk, HR = 1.313, FDR = 0.039390):** CD73 ecto-enzyme; role in immune evasion and nucleotide metabolism. Relationship: putative regulatory interaction with immune-related genes.  
**SCARA3 (risk, HR = 1.377, FDR = 0.002434):** Scavenger receptor; role in lipid handling and inflammation signaling. Relationship: indirect relationship within metabolic networks.  
**TPM4 (risk, HR = 1.364, FDR = 0.00891):** Tropomyosin isoform; role in cytoskeletal stability and motility. Relationship: co-expression with NIN within the EMT program.  
**ATP23 (protective, HR = 0.6885, FDR = 0.006636):** Mitochondrial peptidase/chaperone; role in the mitochondrial ATP program. Relationship: pathway co-membership with NDUFA9 and ATP5 genes.  
**DCBLD2 (risk, HR = 1.408, FDR = 0.008647):** Discoidin domain receptor; role in signaling and EMT. Relationship: regulatory interaction with ZEB1-AS1.  
**FGF19 (risk, HR = 1.291, FDR = 0.051227):** Fibroblast growth factor; role in mitogenic signaling. Relationship: indirect relationship with receptor pathways.

**4. Validation priorities**  
**Mechanistic hypothesis:** Functional validation of INHBB in CRC cell lines or patient-derived organoids. Why it deserves prioritization: strongest FDR among risk genes and direct literature support for poor-prognosis role. Evidence provided by current dataset (HR and FDR) plus disease-association literature. External evidence supports the hypothesis but does not prove causality in OS. Most appropriate next step: CRISPR knockout and assessment of proliferation/invasion/metastasis. Classification: Supported hypothesis.  

**Biomarker:** Independent-cohort validation of CDX2 and INHBB as OS-associated markers. Why it deserves prioritization: CDX2 has established CRC differentiation role; INHBB has high statistical significance. Evidence provided by current dataset (HR values). External evidence includes published CRC studies. Most appropriate next step: testing in TCGA or GEO survival cohorts. Classification: Supported hypothesis.  

**Interaction/network hypothesis:** Experimental confirmation of STRING interactions among mitochondrial (NDUFA9, ATP23) and EMT (TPM4, ZEB1-AS1) genes. Why it deserves prioritization: STRING edges (42 total) suggest network potential within selected genes. Evidence provided by current dataset plus STRING records. External evidence is annotation-based only. Most appropriate next step: co-immunoprecipitation or proximity ligation assays. Classification: Exploratory hypothesis.  

**Confounding or composition check:** Assess tumor purity (e.g., via ESTIMATE or deconvolution algorithms) and correlate with gene-expression levels or HRs, especially for mitochondrial genes. Why it deserves prioritization: mitochondrial genes are sensitive to stromal/immune admixture in tumor tissue. Evidence provided by current dataset (expression and HR values). External evidence argues against specific confounding in the supplied data but notes general tissue-composition issues. Most appropriate next step: laser-capture microdissection or IHC-based purity scoring. Classification: Confounding or composition check.  

**5. Evidence grounding**  
All major programs rest on direct evidence from the input dataset (HR, P, FDR values) for gene associations; pathway/KEGG annotations supply program-level context; disease-association evidence derives from published literature for genes such as INHBB (Europe PMC 41992239) and CDX2 (PubMed 30631044); expression/tissue-specific evidence is limited to the colorectal tumor context; no independent-cohort statistics are available, so external records serve only as plausibility support rather than replication. Protein-interaction evidence (STRING) is annotation-based and not independent of the dataset. No conflicting evidence noted; claims labeled insufficient evidence are avoided where dataset support exists.

**6. Limitations and alternative explanations**  
- Potential batch or platform effects in the microarray data (presence of PROBE_ identifiers).  
- Unaddressed tumor purity and cell-composition differences, which could bias mitochondrial gene signals.  
- Unknown treatment exposure (chemotherapy, targeted therapy) that may confound OS associations.  
- Small number of genes reaching strict FDR thresholds (only 8 with FDR ≤ 0.01), limiting statistical power.  
- Association-versus-causation ambiguity inherent to HR-based prognostic modeling.  

Tumor-purity confounding could be experimentally distinguished by comparing HRs in microdissected tumor versus stromal-rich samples or by multivariable regression adjusting for purity scores derived from bulk RNA-seq.  

The current dataset provides a robust starting point for hypothesis generation in CRC prognosis but requires independent validation to establish clinical utility.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=20, external claims checked=0, external mismatches=0, status=passed.

Answer model API: xAI / grok-4.6

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
